However, the use of small molecule EGFR tyrosine kinase inhibitors (TKIs) alone has shown minimal clinical effectiveness though with reduced side effects as compared with conventional chemotherapeutic drugs in breast cancer patients.9 The gene discussed is EGFR; the disease is breast cancer.